Treatment of upper and lower respiratory tract infections: Clinical trials with cefprozil

Pediatric Infectious Disease Journal

Volumn 17, Issue 8 SUPPL., 1998, Pages

  Aronovitz, Gerson ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Bronchitis; Cefprozil; Otitis media; Pharyngitis tonsillitis; Sinusitis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFACLOR; CEFIXIME; CEFPROZIL; ERYTHROMYCIN; PENICILLIN G;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BRONCHITIS; CLINICAL FEATURE; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; LOWER RESPIRATORY TRACT INFECTION; PATIENT ATTITUDE; PHARYNGITIS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; TONSILLITIS; TREATMENT INDICATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 0031812803     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199808001-00007     Document Type: Review

References (25)

1. Thornsberry C. Activity of selected antimicrobials against penicillin-resistant S. pneumoniae isolates. Infect Med 1997; 14(Suppl A):13-9.
2. Fung-Tomc JC, Huczko E, Stickle T, et al. Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides. Antimicrob Agents Chemother 1995;39: 533-8.
3. Kessler R, Fung-Tomc J. In vitro activity of cefprozil compared with other cephalosporins. Infect Med 1992;9(Suppl C): 10-18.
4. Thornsberry C, Burton P, Vanderhoof B, Ogilvie P. Regional differences in beta-lactamase and ampicillin and cefprozil resistance in Haemophilus influenzae in the United States. Adv Ther 1996;13:301-11.
5. Cappelletty DM, Rybak MJ. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model. Antimicrob Agents Chemother 1996;40:1148-52.
6. Aronovitz GH, Doyle CA, Durham SJ, Wilber RB, Materman E, Simonson C. Cefprozil vs. amoxicillin/clavulanate in the treatment of acute otitis media. Infect Med 1992;9(Suppl C):19-32.
7. Arguedas AG, Zaleska M, Stutman HR, Blumer JL, Hains CS. Comparative trial of cefprozil vs. amoxicillin clavulanate potassium in the treatment of children with acute otitis media with effusion. Pediatr Infect Dis J 1991;10:375-80.
8. Poole JM, Rosenberg R, Aronovitz GH, et al. Cefprozil vs. cefixime and cefaclor in otitis media in children. Infect Med 1992;9(Suppl E):21-32.
9. Pichichero ME, McLinn S, Aronovitz G, et al. Cefprozil treatment of persistent and recurrent acute otitis media. Pediatr Infect Dis J 1997;16:471-8.
10. Data on file. Princeton, NJ: Bristol-Myers Squibb, 1997.
11. Shyu WC, Haddad J, Reilly J, et al. Penetration of cefprozil into middle ear fluid of patients with otitis media. Antimicrob Agents Chemother 1994;38:2210-12.
12. Milatovic D, Adam D, Hamilton H, Materman EI. Cefprozil versus penicillin V in the treatment of streptococcal tonsillopharyngitis. Antimicrob Agents Chemother 1993;37:1620-3.
13. De la Garza CA, Nolen TM, Rogan MP. Cefprozil vs. erythromycin in streptococcal tonsillopharyngitis. Infect Med 1992;9(Suppl E):8-20.
14. Doyle CA, Durham SJ, Hamilton HA, Wilber RB. Cefprozil vs. cefaclor in the treatment of pharyngitis and tonsillitis in adults. Infect Med 1992;9(Suppl E):66-7.
15. van den Wijngaart W, Verbrugh H, Theopold HM, et al. A noncomparative study of cefprozil at two dose levels in the treatment of acute uncomplicated bacterial sinusitis. Clin Ther 1992;14:306-13.
16. Russell MD, Nolen T, Allen JM, Skuba K, DeRegis RG, Nicaise C. Cefprozil versus amoxicillin/clavulanate in the treatment of acute, uncomplicated maxillary sinusitis in adults. A randomized, prospective clinical trial. Infect Med 1997;14(Suppl A):43-50.
17. Adelglass J, Bundy JM, Bacterial Sinusitis Study Group. Comparison of cefprozil and amoxicillin/clavulanate in the treatment of adults with acute bacterial sinusitis [Abstract LM-37]. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17 to 20, 1995. Washington, DC: American Society for Microbiology, 1995:333.
18. Simon MW. A prospective randomized study comparing the efficacy of amoxicillin-clavulanate, erythromycin-sulfisoxazole, cefaclor, and cefprozil in treating acute sinusitis of childhood. Adv Ther 1997;14:64-72.
19. Bonnet JP, Ginsberg D, Nolen TM, et al. Cefprozil vs. cefuroxime axetil in mild to moderate lower respiratory tract infections: a focus on bronchitis. Infect Med 1992;9(Suppl E):48-56.
20. Barbarash RA, Solomon E, Thieneman A Jr, et al. Cefprozil vs. amoxicillin/clavulanate in mild to moderate lower respiratory tract infections: a focus on bronchitis. Infect Med 1992;9(Suppl E):40-7.
21. Wilber RB, Hamilton H, Leroy A, et al. Cefprozil vs. cefaclor in the treatment of lower respiratory tract infections: a focus on bronchitis. Infect Med 1992;9(Suppl E):33-9.
22. Sappington RF Jr, Fogarty C, Nolen TM, Brandon ML. A multicenter study of cefprozil vs clarithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis. Infect Med 1997;14(Suppl A):61-8.
23. Puopolo A, Littlejohn TW, Nolen T, Dewan M, Ziering WH. A randomized, multicenter, comparative trial of cefprozil and cefuroxime axetil in the treatment of acute bacterial bronchitis and AECB. Infect Med 1997;14(Suppl A):51-69.
24. Kalish GH. Satisfaction with outcome as a function of patient expectation: the National Antibiotic Patient Satisfaction Surveys. Health Care Innovations 1996;6:9-12, 29-33.
25. Wilber RB, Doyle CA, Durham SJ, Connetta BJ, DeGraw SS, Leigh A. Safety profile of cefprozil. Clin Infect Dis 1992; 14(Suppl 2):S264-71.